Document is current

Any future updates will be listed below

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

Crossref DOI link: https://doi.org/10.1007/s10147-022-02286-7

Published Online: 2023-01-17

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark